Emerging concepts on drug resistance in bladder cancer: Implications for future strategies

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 81-90

  Massari, Francesco ^a   Santoni, Matteo ^b   Ciccarese, Chiara ^a   Brunelli, Matteo ^a   Conti, Alessandro ^b   Santini, Daniele ^c   Montironi, Rodolfo ^b   Cascinu, Stefano ^b   Tortora, Giampaolo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bladder cancer; Drug resistance; Personalized medicine

Indexed keywords

CARRIER PROTEIN; CISPLATIN; COPPER TRANSPORTER 1; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR; GEMCITABINE; GLUTATHIONE; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PAZOPANIB; PLACEBO; PLATINUM DERIVATIVE; PROTEIN INHIBITOR; PROTEIN P53; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR NRF2; TRIENTINE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR INHIBITOR; VINFLUNINE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER RESISTANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOHISTOCHEMISTRY; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; URETHRA CANCER; URINARY TRACT CANCER; DRUG RESISTANCE; PATHOLOGY; URINARY BLADDER NEOPLASMS;

DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 84942195910     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.005     Document Type: Review

References (86)

1. Foster C.S., Ross J.S. Pathology of the urinary bladder 2004, 183-267. Saunders, Philadelphia, US.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012, 62:10-29.
3. Roth B.J., Bajorin D.F. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 1995, 153:894-900.
4. Von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23:4602-4608.
5. Yafi F.A., North S., Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 2011, 18:e25-e34.
6. Pond G.R., Bellmunt J., Fougeray R., et al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer 2013, 11:495-500.
7. Millard F. Update on chemotherapy in the treatment of urothelial carcinoma. Sci. World J 2011, 11:1981-1994.
8. Albers P., Park S.I., Niegisch G., et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011, 22:288-294.
9. Naiki T., Kawai N., Hashimoto Y., et al. Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. Int J Clin Oncol 2014, 19:516-522.
10. Dogliotti L., Cartenì G., Siena S., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007, 52:134-141.
11. Furuta T., Ueda T., Aune G., et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002, 62:4899-4902.
12. Matsunaga T., Mu D., Park C.H., Reardon J.T., Sancar A., Human D.N.A. Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 1995, 270:20862-20869.
13. Usanova S., Piée-Staffa A., Sied U., et al. Cisplatin sensitivity of testis tumour cells due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010, 9:248.
14. Bellmunt J., Paz-Ares L., Cuello M., et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007, 18:522-528.
15. Smith D.H., Fiehn A.M., Fogh L., et al. Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. Sci Rep 2014, 4:4313.
16. Friboulet L., Olaussen K.A., Pignon J.P., et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013, 368:1101-1110.
17. Friboulet L., Postel-Vinay S., Sourisseau T., et al. ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Cell Cycle 2013, 12:3298-3306.
18. Hoffmann A.C., Wild P., Leicht C., et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12:628-636.
19. Sun J.M., Sung J.Y., Park S.H., et al. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer 2012, 12:187.
20. Kawashima A., Takayama H., Tsujimura A. A review of ERCC1 gene in bladder cancer implications for carcinogenesis and resistance to chemoradiotherapy. Adv Urol 2012, 2012. 812398.
21. Kawashima A., Nakayama M., Kakuta Y., et al. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 2011, 17(8):2561-2569.
22. Buisson R., Dion-Côté A.M., Coulombe Y., et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 2010, 17:1247-1254.
23. Font A., Taron M., Gago J.L., et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011, 22:139-144.
24. Li N., Alam J., Venkatesan M.I., et al. Nrf2 is a key transcription factor that regulates antioxidant defense in macrophages and epithelial cells: protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals. J Immunol 2004, 173:3467-3481.
25. Hayden A., Douglas J., Sommerlad M., et al. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol Oncol 2014, pii S1078-1439(14)00037-4. 10.1016/j.urolonc.2014.02.006.
26. Ishida S., Lee J., Thiele D.J., Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast mammals. Proc Natl Acad Sci USA 2002, 99:14298-14302.
27. Komatsu M., Sumizawa T., Mutoh M., et al. Copper transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000, 60:1312-1316.
28. Beretta G.L., Gatti L., Tinelli S., et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 2004, 68:283-291.
29. Huang C.P., Fofana M., Chan J., Chang C.J., Howell S.B. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics 2014, 6:654-661.
30. Schmid S.C., Schuster T., Horn T., Gschwend J., Treiber U., Weirich G. Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer. Anticancer Res 2013, 33:3731-3737.
31. Calin G.A. MicroRNA signatures in human cancers. Nat Rev 2006, 6:857-866.
32. Zabolotneva A.A., Zhavoronkov A., Garazha A.V., Roumiantsev S.A., Buzdin A.A. Characteristic patterns of microRNA expression in human bladder cancer. Front Genet 2013, 3:1-5.
33. Pignot G., Cizeron-Clairac G., Vacher S., et al. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 2013, 132:2479-2491.
34. Rose W.C., Basler G.A. In vivo model development of cisplatin-resistant and -sensitive A2780human ovarian carcinomas. In Vivo 1990, 4:391-396.
35. Drayton R.M., Dudziec E., Peter S., et al. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 2014, 20:1990-2000.
36. McConkey D.J., Choi W., Marquis L., et al. Role of epithelialto-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009, 28:335-344.
37. Gee J., Greathead P., Little A.F., et al. Aberrant cadherin expression in bladder carcinoma cells. Mol Urol 1998, 2:73-81.
38. Kawashima A., Takayama H., Kawamura N., et al. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncol Lett 2012, 4:15-21.
39. Abat D., Demirhan O., Inandiklioglu N., et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett 2014, 8:25-32.
40. Esrig D., Spruck C.H., Nichols P.W., et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993, 143:1389-1397.
41. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264.
42. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993, 85:53-59.
43. Lipponen P.K. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993, 53:365-370.
44. Stadler W.M., Lerner S.P., Groshen S., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol 2011, 29:3443-3449.
45. Sarkis A.S., Bajorin D.F., Reuter V.E., et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995, 13:1384-1390.
46. Choi W., Porten S., Kim S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25(2):152-165.
47. Mackey J.R., Mani R.S., Selner M., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998, 58:4349-4357.
48. Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004, 95:753-757.
49. Spratlin J., Sangha R., Glubrecht D., et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004, 10:6956-6961.
50. Farré X., Guillén-Gómez E., Sánchez L., et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 2004, 112:959-966.
51. Mey V., Giovannetti E., De Braud F., et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006, 95:289-297.
52. Matsumura N., Nakamura Y., Kohjimoto Y., et al. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int 2011, 108:E110-E116.
53. Kozinn S.I., Harty N.J., Delong J.M., et al. MicroRNA profile to predict gemcitabine resistance in bladder carcinoma cell lines. Genes Cancer 2013, 4:61-69.
54. Jordheim L.P., Seve P., Tredan O., Dumontet C. The ribo-nucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 2011, 12:693-702.
55. Gong W., Zhang X., Wu J., et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012, 75:374-380.
56. Shilkrut M., Wu A., Thomas D.G., Hamstra D.A. Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive muscle invasive bladder cancer treated with chemotherapy and radiation. Mol Clin Oncol 2014, 2:479-487.
57. Sève P., Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?. Lancet Oncol 2008, 9:168-175.
58. Choi J.W., Kim Y., Lee J.H., Kim Y.S. Expression of b-tubulin isotypes in urothelial carcinoma of the bladder. World J Urol 2014, 32:347-352.
59. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
60. Chen Y., Li L., Zeng J., et al. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Chemotherapy 2012, 58:264-272.
61. Nakagawa M., Enokida H., Gotanda T., et al. Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line. Aktuelle Urol 2003, 34:250-252.
62. Li Y., Yang X., Su L.J., Flaig T.W. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology 2011, 78(233):e7-e13.
63. Kavallaris M., Annereau J.P., Barret J.M. Potential mechanisms of resistance to microtubule inhibitors. Semin Oncol 2008, 35:S22-S27.
64. Chow N.H., Tzai T.S., Lin S.N., Chan S.H., Tang M.J. Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma. Eur Urol 1993, 24:140-143.
65. Kim W.T., Kim J., Yan C., et al. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol 2014, 25:974-979.
66. Hsieh T.F., Chen C.C., Ma W.L., et al. Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncol Rep 2013, 30:2917-2922.
67. Bellmunt J., Teh B.T., Tortora G., Rosenberg J.E. Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol 2013, 10:557-570.
68. Adam L., Zhong M., Choi W., et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009, 15:5060-5072.
69. Di Martino E., Tomlinson D.C., Knowles M.A. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012, 2012:429213. 10.1155/2012/429213.
70. Tomlinson D.C., Baldo O., Harnden P., Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213:91-98.
71. Burger M., van der Aa M.N., van Oers J.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 2008, 54:835-843.
72. Kompier L.C., van der Aa M.N., Lurkin I., et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol 2009, 218:104-112.
73. Tomlinson D.C., Knowles M.A. Altered splicing of FGFR1 is associated with high tumour grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 2010, 177:2379-2386.
74. Tomlinson D.C., Lamont F.R., Shnyder S.D., Knowles M.A. Fibroblast growth factor receptor promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009, 69:4613-4620.
75. Hänze J., Henrici M., Hegele A., Hofmann R., Olbert P.J. Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer 2013, 13:589.
76. Kopparapu P.K., Boorjian S.A., Robinson B.D., et al. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 2013, 33:2381-2390.
77. Xia G., Kumar S.R., Hawes D., et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006, 175:1245-1252.
78. Grivas P.D., Daignault S., Tagawa S.T., et al. Doubleblind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 2014, 120:692-701.
79. Galsky M.D., Hahn N.M., Powles T., et al. Gemcitabine cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013, 11:175-181.
80. Gallagher D.J., Milowsky M.I., Gerst S.R., et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010, 28:1373-1379.
81. Dreicer R., Li H., Stein M., et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009, 15(115):4090-4095.
82. Sridhar S.S., Winquist E., Eisen A., et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH phase II consortium. Invest New Drugs 2011, 29:1045-1049.
83. Pili R., Qin R., Flynn P.J., et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 2013, 11:477-483.
84. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 11(132):27-42.
85. Santoni M., Amantini C., Morelli M.B., et al. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer 2013, 109:1040-1050.
86. Ge J., Chen Z., Huang J., et al. Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer. PLoS ONE 2014, 9:e110293.